Status:
UNKNOWN
Detection of FGFR Gene Mutations in the Tumor Tissue and Urine of Patients With Urothelial Carcinoma
Lead Sponsor:
Ho Kyung Seo
Conditions:
Bladder Cancer
Eligibility:
All Genders
20-90 years
Brief Summary
This study aims to compare the correlation between FGFR mutations found in bladder cancer tissues and urine to develop a companion diagnostic method for predicting the effect of FGFR inhibitors using ...
Detailed Description
This study targets 92 patients with urothelial cancer, whose tissue (from scheduled surgery) and urine samples can be obtained, regardless of the treatment stage. ■ Examination Methods * FGFR mutati...
Eligibility Criteria
Inclusion
- Suspected patients of urothelial cancer who will visit the National Cancer Center Korea from the date of Institutional Review Board (IRB) approval to 2021 and with identified tumors in the bladder according to bladder endoscopy.
- Subjects who are scheduled for surgery (transurethral bladder tumor resection, radical bladder resection, and radical bladder ureterectomy) and have agreed to participate in the study
Exclusion
- History of other active malignant tumors treated within 24 months
- Patients with either mental illness or who cannot participate in clinical trials at the judgment of other doctors
- If patients and guardians do not want to participate in this study
- History of having administered FGFR inhibitors in the past
Key Trial Info
Start Date :
May 1 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 31 2025
Estimated Enrollment :
92 Patients enrolled
Trial Details
Trial ID
NCT04339933
Start Date
May 1 2022
End Date
March 31 2025
Last Update
April 7 2022
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.